Open Up Your Eyes: FDA Expects Real Transparency in Disclosures

Based on client inquiries and FDA actions, the Food and Drug Administration is focusing more on companies not submitting data to It is taking stronger action against those companies it believes are non-compliant….
By: Arnall Golden Gregory LLP
Previous Story

As The PIP World Turns: Insurance Carriers Do Not Have To Pay 100% Of The Billed Amounts Under Section 627.736, Florida Statutes

Next Story

Janssen Pharms., Inc. v. Tolmar, Inc. – Invega Sustenna┬« (Paliperidone Extended-Release Suspension)